U.S. Food Stock News

Tenaya Therapeutics recently announced a research collaboration with Alnylam Pharmaceuticals to validate up to 15 gene targets for cardiovascular disease over two years, with Tenaya receiving up to US$10,000,000 upfront plus cost reimbursement and potential milestone payments of up to US$1.13 billion if all targets lead to approved therapies. This agreement could broaden Alnylam’s RNAi pipeline beyond its core transthyretin focus by adding genetically validated cardiovascular targets that...

Welltower Inc. recently closed an amended US$6.25 billion senior unsecured revolving credit facility, extending maturities to 2029–2030, modestly reducing pricing, and using cash on hand to repay its prior US$1.00 billion and C$250.00 million term loans while increasing total available credit facilities to about US$7.50 billion. By improving its credit outlook, lowering its borrowing spread to 67.5 basis points over SOFR, and adding the option to further upsize the facility, Welltower has...

Pfizer, NYSE:PFE, has secured multi year exemptions from proposed 100% US tariffs on imported patented medicines. In return, the company has agreed to invest $70b in US based R&D and manufacturing over several years. The agreement also includes regulatory grace periods, while many peers face disruption from the pending tariff regime. Pfizer shares trade at $27.16, with the stock up 7.9% year to date and 12.1% over the past year, although the 3 year return is an 18.4% decline. This mix of...

If you are wondering whether Equinix is priced attractively or already reflects a lot of optimism, you are in the right place to unpack what the current share price might be implying. At a recent close of US$956.07, Equinix has posted a 12.7% return over the last 30 days, 25.1% year to date, and 17.0% over the past year, with a 47.3% return over 3 years and 57.0% over 5 years, despite a 1.6% decline in the last week. Recent attention on Equinix has been driven more by its role in digital...

Yalla Group (YALA) has rounded out FY 2025 with fourth quarter revenue of about US$83.9 million and basic EPS of US$0.23, against a trailing twelve month EPS of US$0.96 that sits alongside earnings growth of 10.4% year on year. Over the past six quarters in the dataset, revenue has moved within a tight band between roughly US$83.9 million and US$90.8 million per quarter, while quarterly EPS has ranged from about US$0.20 to US$0.27, feeding into a trailing net profit margin of 43.8% that is...

If you are wondering whether Applied Materials' current share price still offers value after a big run, this article walks through how its valuation stacks up using several common methods. The stock recently closed at US$345.88, with returns of 7.2% over the past 30 days, 28.6% year to date, and 137.4% over the last year, which has reshaped how many investors think about its risk and return profile. Recent news around the broader semiconductor and AI supply chain has kept Applied Materials...

General Mills (GIS) stock is back in focus after Q2 2026 results highlighted about 25% growth in new product innovation, market share gains in 8 of its top 10 categories, and management’s more confident second half outlook. See our latest analysis for General Mills. Despite the Q2 2026 update and recent product news around K 12 reformulations and entertainment tie ins, momentum in the shares has been weak. A 30 day share price return of 11.68% and a 1 year total shareholder return of 28.77%...

GE HealthCare Technologies (GEHC) just secured FDA 510(k) clearance for View, its cloud-native diagnostic viewer within the Genesis Radiology Workspace. This regulatory milestone could influence how investors think about the stock. See our latest analysis for GE HealthCare Technologies. Despite the FDA clearance for View and a steady stream of product news and conference appearances in early March, GE HealthCare’s share price has been under pressure, with a 30 day share price return of 9.82%...

Why CG Oncology Is On Investors’ Radar CG Oncology (CGON) has been drawing attention after a strong run in recent months, with the stock showing double digit gains over the past month and past 3 months. See our latest analysis for CG Oncology. With the share price at $62.80, CG Oncology has seen a 24.7% 1 month share price return and a 50.3% year to date share price return, while the 1 year total shareholder return stands at 138.8%, pointing to strong momentum over both shorter and longer...

If you are wondering whether Mastercard is priced fairly or if the recent weakness has opened a window of opportunity, this breakdown will help you see what the current share price actually implies. After a strong multi year run, with a 48.5% return over 3 years and 38.5% over 5 years, the stock is currently below its recent levels, with a 1.8% decline over 7 days, 6.2% over 30 days and 8.6% year to date, leaving it 1.5% lower over the past year. Recent attention on Mastercard has focused on...

If you are wondering whether ASML Holding's lofty share price still makes sense, you are not alone. This article focuses squarely on what you might be paying for and what you are getting in return. ASML's shares last closed at US$1,383.40, with returns of 1.7% over 7 days, a 2.1% decline over 30 days, 18.9% year to date, 101.9% over 1 year and 128.1% over 3 years. These figures raise fair questions about how much optimism is already reflected in the price. Recent attention on ASML has...

If you are wondering whether Paramount Skydance's current share price reflects its true worth, you are not alone. This article will walk through what the numbers say about its value. The stock last closed at US$10.33, with returns of a 17% decline over 7 days, a 2.2% decline over 30 days, a 21.6% decline year to date, an 8.6% decline over 1 year, a 44.4% decline over 3 years, and an 88.0% decline over 5 years. These moves may have reshaped how investors see its potential and risk. Recent...

Feathery has launched what it calls the first one click Schwab account API, allowing advisory firms to open NYSE:SCHW accounts directly from their own onboarding workflows. The integration is designed to cut manual data entry, reduce errors, and speed up client onboarding for advisors using Schwab as their custodian. The release also includes expanded onboarding capabilities that aim to standardize and automate more of the account opening process across advisory firms. For a firm like...

On 9 March 2026, Aon plc announced completing the first known stablecoin insurance premium payments among major global brokers, working with clients Coinbase and Paxos to settle premiums in trusted U.S. dollar-backed stablecoins across multiple blockchains, including USDC on Ethereum and PayPal USD on Solana. This move highlights Coinbase’s expanding role as compliant infrastructure for institutional use of stablecoins in traditional financial services, potentially deepening its ties with...

Kronos Worldwide (KRO) closed out FY 2025 with Q4 revenue of US$418.3 million and a basic EPS loss of US$0.72, capping off a trailing twelve month period where revenue totaled US$1.9 billion and basic EPS came in at a loss of US$0.96. Over recent quarters, the company has seen revenue move from US$423.1 million and basic EPS of a US$0.11 loss in Q4 2024 to US$489.8 million with EPS of US$0.16 in Q1 2025, before stepping down to US$456.9 million and a US$0.32 loss in Q3 2025 and ending at...

Stryker (NYSE:SYK) has launched its new SmartHospital Platform, a digital solution for hospitals. The platform is designed to unify devices, data, and care teams across clinical settings. Key features include voice-activated communication, a workflow engine, virtual care support, and ambient intelligence tools. Stryker is widely known for its medical devices and equipment, and the SmartHospital Platform adds a broader digital layer on top of that hardware footprint. By focusing on workflow...

Recent performance and context for CECO Environmental With no specific news event driving headlines today, CECO Environmental (CECO) still sits on investors’ radar after a mixed run, including a recent 25% decline over the past month and 6.8% decline over the past 3 months. See our latest analysis for CECO Environmental. Despite the recent 24.9% 1 month share price decline and 6.8% 3 month share price decline, CECO Environmental’s 1 year total shareholder return of 136.9% and very large 5...

GameStop at a glance GameStop (GME) continues to draw attention from retail investors, with the share price at $24.37 and an implied intrinsic discount of 78.47% based on the provided valuation estimate. Recent returns show mixed momentum, with a 1 day decline of 1.73%, a 7 day gain of 2.31%, a 2.44% decline over the past month, and a 10.17% gain over the past 3 months. See our latest analysis for GameStop. For context, GameStop’s share price return has been positive year to date at 18.19%,...

SIGA Technologies, Inc. reported past fourth-quarter 2025 revenue of US$3.8 million versus US$81.4 million a year earlier, swinging from net income of US$45.7 million to a net loss of US$5.4 million. For 2025 as a whole, revenue fell to US$94.57 million and net income to US$23.28 million, even as SIGA secured a new US$13 million oral TPOXX procurement order in the Asia Pacific region in January 2026. We’ll now examine how the earnings decline alongside the new Asia Pacific TPOXX contract...

If you are wondering whether Ambarella's current share price offers value or just more volatility, you are not alone and this article is here to help you weigh that up clearly. The stock last closed at US$54.00, with returns of a 4.5% decline over 7 days, a 17.2% decline over 30 days, a 28.2% decline year to date, a 3.8% gain over 1 year, a 29.5% decline over 3 years and a 51.2% decline over 5 years. Taken together, this gives you a mixed picture of short term pressure and longer term swings...

If you are wondering whether Lazard's current share price still reflects its true worth, you are not alone. The stock has been attracting attention from investors asking exactly that question. Lazard closed at US$43.04, with recent returns of a 12.4% decline over 7 days, a 24.2% decline over 30 days, a 13.5% decline year to date and a 2.5% decline over 1 year. The 3 year and 5 year returns stand at 50.1% and 23.7% respectively. Recent news flow around Lazard has centered on its role as a...

MacroGenics (MGNX) has wrapped up FY 2025 with fourth quarter revenue of US$41.2 million and a basic EPS loss of US$0.22, as the market weighs these results against a share price of US$3.43. The company has seen revenue move from US$110.7 million in Q3 2024 to US$72.8 million in Q3 2025, while basic EPS shifted from a profit of US$0.90 to a profit of US$0.27 over the same period, creating a mixed picture on topline scale and per share results. Overall, margins remain under pressure, which...

If you are wondering whether Quanta Services at around US$564 per share still offers value after a huge run, you are not alone. This article is built to help you frame that question clearly. The stock has been volatile in the short term, with a 0.3% decline over the last 7 days, but the 1 month return of 11.0%, year to date return of 28.3%, 1 year return of 129.5% and a very large 5 year gain hint that the market has been steadily rethinking what this business is worth. Recent news coverage...

NewMarket stock at a glance NewMarket (NEU) has caught investor attention after recent trading left the shares with a month return of about a 14% decline and a past 3 months return near a 19% decline. See our latest analysis for NewMarket. Despite the recent 30 day share price return of about a 14% decline and a 90 day share price return near a 19% decline, NewMarket’s 1 year total shareholder return of about 15% and multi year total shareholder returns above 70% indicate longer term holders...